Moderna Therapeutics emerged from stealth mode with a $40 million financing led by Flagship Ventures and a consortium of private investors. Moderna is developing a platform technology for delivery of messenger RNA (mRNA) to stimulate production of therapeutic proteins in the cells. Read More
LONDON – Two major networks of genes and their encoded proteins, involved in lipid metabolism and inflammation, play an important role in determining a person's risk of developing coronary artery disease (CAD), a new study has found. Read More
• Vical Inc., of San Diego, said it inked a worldwide, nonexclusive license for rights to its Vaxfectin adjuvant to Cyvax Inc., a privately held vaccine firm, for use in malaria vaccines. Financial terms were not disclosed. Read More
• Pfizer Inc., of New York, said randomized Phase II data showed that PD-0332991 in combination with letrozole significantly extended progression-free survival (PFS) compared to letrozole alone in postmenopausal women with estrogen receptor-positive human epidermal growth factor receptor-1-negative locally advanced or metastatic breast cancer. Read More
• Astellas Pharma Inc., of Tokyo, said the FDA accepted for review its new drug application for tacrolimus extended-release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients. The PDUFA data will be July 21, 2013. Read More
• Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it reached an agreement with the FDA on the design of a single registration trial testing Cotara in patients with recurrent glioblastoma multiforme. Read More
